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Abstract 
Background: Advances in malaria control have reduced the burden of disease resulting from exposure to parasite 
infections. The consequences on naturally acquired immunity are unclear. A magnetic bead‑based immunoassay 
(MBA) to assess antibody levels in populations living in endemic areas was previously evaluated. In this study, the 
effect of clinical attacks on immunity was analysed in three sentinel sites of Ivory Coast.
Methods: Recombinant proteins or peptides derived from liver or blood stage antigens of Plasmodium falciparum 
(CSP, LSA141, LSA3, SALSA, PF13‑DBL1α1, GLURP, AMA1, MSP1p19, MSP4p20), the CSP of Plasmodium malariae and 
the salivary glands antigen of Anopheles gambiae (gSG6) were covalently linked to a colour‑coded microsphere 
(Luminex™ beads) for the multiplex assay. ELISA was used for whole parasite extract antigen. Blood samples (n = 94) 
of patients consulting for symptomatic malaria attacks and living in three different malaria endemic settings (rural and 
periurban) were analysed.
Results: Highly variable seroprevalence of antibody responses against parasite antigens was found ranging from 3 
(gSG6) to 97 % (MSP4p20). A marked prevalence and significantly higher level of antibodies was found in patients 
from the rural site (Korhogo), those harbouring the lowest level of parasitaemia. The use of whole schizont extract 
could not discriminate immunity level, contrary to parasite‑derived recombinant proteins or peptides. Prevalence 
of responders to LSA141 and levels of antibodies to PF13 were significantly different between the three settings. 
Moreover, the post‑treatment clearance of parasites was clearly associated with a significantly higher level of antibody 
response for almost 50 % of the parasite antigens tested.
Conclusion: The multiplex MBA‑Magpix technology assay provides an accurate high throughput monitoring of 
parasite‑specific antibodies during symptomatic malaria. The levels of antibody responses may provide a risk criterion 
with respect to the degree of parasitic infection. Additionally, they can be used as an indicator in the implementation 
of malaria prevention and local control strategies.
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Background
Malaria is caused by a protozoan parasite of the genus 
Plasmodium. In Ivory Coast, malarial endemicity has 
been shown to be heterogeneous, depending upon vari-
ous bio-ecological areas [1]. The spread and occurrence 
of malaria varies widely between villages and even within 
the same village. Malaria surveillance is monitored 
through a national malaria control programme (NMCP) 
and follow-up with relevant sentinel sites around the 
country. It has been established that areas of unstable, 
low, malaria transmission such Gambia and Kenya are 
characterized by a persistent risk of clinical malaria in 
older children and adults whereas in areas with stable, 
high-level of malaria transmission the risk of clinical 
malaria decreases markedly after the age of 5 years [2, 3].
In the recent years, the large-scale deployment of 
combined interventions strategies, including insecticide 
impregnated bed nets, rapid diagnostic tests and efficient 
combination therapy, led to a decrease of malaria burden 
in several sub-Saharan African areas [4]. Several tools are 
useful for follow-up progress of controls and decrease of 
malaria burden. For estimating the risk of malaria trans-
mission or infection, the entomological inoculation rate 
(EIR) is considered as a gold standard. The EIR is esti-
mated by the number of mosquito bites per man per 
night multiplied by the proportion of sporozoite positive 
mosquitoes [5]. Presently, with the decreasing transmis-
sion rate resulting from enlarged control programmes 
and scarcity of positive mosquitoes makes this method 
labour-intensive.
Another potential indicator of malaria transmission 
relies on ELISA-based serology investigations by measur-
ing antibody responses against a set of antigens to evalu-
ate exposure, such as mosquito salivary antigen [5–7], or 
different parasite-associated target antigens potentially 
associated with protection to malaria [8–10]. However, 
this technique can be used only for a limited number 
of antigens. Therefore, new strategy such as multiplex 
fluorescent bead-based assays have been developed by 
Luminex® Corporation and allows the simultaneous 
testing of several serological markers together, provid-
ing capacity for accurate high throughput monitoring of 
malaria immunity [11–14].
Passive transfer experiments demonstrated that anti-
bodies are major determinants of malarial protec-
tive immunity in human [15, 16]. Immunoglobulin G 
(IgG) antibody responses to a number of vaccine can-
didate antigens, including pre-erythrocytic antigens 
circumsporozoite protein (CSP) [17], liver-stage antigen 
1 (LSA1) [17, 18], the blood-stage antigens as the mero-
zoite surface protein 1 (MSP1) [19–21] and the Apical 
Membrane Antigen 1 (AMA1) [22]. These antigens have 
been associated with protection from clinical malaria in 
an area of stable transmission. Antibody responses to 
such vaccine candidates can also be investigated for use as 
indicators of past and recent malaria transmission. In the 
context of ongoing malaria elimination strategy, changes 
and variations of antibody responses in different settings 
could take place as useful monitoring tool requiring com-
bination of different markers [10, 11, 19, 20, 23].
In the present study, malaria-related immunity was 
analysed by measuring antibody responses against 12 
recombinant and peptide parasite antigens in individuals 
from Ivory Coast using a magnetic bead-based multiplex 
assay [24]. This pilot study involved an array of antigens 
previously investigated [11, 13] with the aim to provide 
immunology-related study in populations from this 
country. Recruitment involved three groups of approxi-
mately 30 patients on the day of consultation for clinical 
attacks in distinct geographical and malaria transmission 
settings.
Different profile and levels of antibody responses 
from malaria symptomatic patients according to differ-
ent transmission settings were evidenced. These results 
indicate that the antibody response to antigens derived 
from Plasmodium falciparum, Plasmodium malariae or 
Anopheles gambiae can also be used as relevant biomark-
ers to evaluate follow-up and prevention measures at 
community level.
Methods
Study area, procedures for recruitment
Subjects were recruited in Korhogo, Man and Abobo, 
three Ivorian malaria-endemic areas included in the Sen-
tinel National Network for Surveillance of Malaria. The 
protocol of surveillance was approved by the National 
Committee of the Ministry of Health. Individual 
informed written consent was obtained from partici-
pants/parents/guardians. In case of an illiterate patient, 
his/her thumb impression and signature of an independ-
ent witness were obtained. The study was conducted in 
accordance with the local laws and regulations, Inter-
national Conference on Harmonization—Good Clini-
cal Practice (ICH-GCP). The protocol was reviewed 
and approved by the Comité National d’Ethique et de 
Recherche de Côte d’Ivoire (N°56/MSLS/CNER-dkn).
Keywords: Malaria, Plasmodium falciparum, ELISA, IgG, Surface antigens, Multiplex, MAGPIX, Ivory Coast, 
Symptomatic malaria, Biomarkers
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Patients were enrolled in the pilot study in September–
November 2013, after the rainy season i.e., after the peak 
of transmission.
Korhogo, located at 9°53′ latitude north and 6°49′ lon-
gitude west, bordering Mali and Burkina Faso, is a savan-
nah area with a tropical climate and a transmission period 
of 6–8 months. The village of Man is located in the west-
ern forest and mountain area, at 7°24′ of latitude north, 
7°33′ longitude west. Rainfall is abundant (1800  mm/
year) and transmission occurs for 8–12 months. The site 
of Abobo is located in the southern part of the township 
of Abidjan, characterized by the presence of a lagoon 
with transmission occurring year round.
Recent data on the cumulative EIR in Korhogo [25] or 
Man were not available [26]. However, in the absence of 
exact EIR, morbidity data collected from health facility 
records in 2013, shown in Table 1, reflect the high level of 
transmission in these endemic areas.
This study involved 94 patients consulting for sympto-
matic fever in health centres: formation sanitaire Anon-
koua-Kouté, centre de santé petit Paris, centre de santé 
urbain de ‘Libreville’, the respective healthcare centre in 
Abobo, Korhogo, Man. Patients were treated and followed 
up according to the standard national procedure. Diagno-
sis of malaria includes rapid diagnostic test (RDT), blood 
sampling for biological investigations and blood smear 
for parasite counting. Parasitaemia was counted on thick 
blood smears by two experienced microscopists. In case 
of discrepancy, smears were confirmed by a third count-
ing. Characteristics of the three groups are summarized 
in Table  1. All patients were hospitalized, treated and 
followed up daily from day 0 to day 3 with artemether–
lumefantrine combination. Parasitaemia was recorded 
every 24 h, up to two consecutive negative blood smears. 
Parasite clearance time (PCT) and its related clinical phe-
notype (delayed PCT) were recorded for each patient. 
These indicators are defined respectively as the time 
between treatment and the first negative slide, and as the 
proportion of patients still parasitaemic on days 2 or 3. An 
individual questionnaire for each patient recorded gravity 
symptoms (graded as none, moderate, intense), the use of 
bed nets and previous unprescribed individual use of anti-
malarials. For all patients, almost complete PCT within 
4  days was observed after treatment. The procedure 
included a recall of patients on days 7, 14, 21, 28, and 42 
for confirmation of complete cure, tolerability and para-
sitological monitoring. No recrudescence of infections 
was recorded in any patients followed up. Plasma samples 
after biology processing at day 0 were collected upon cen-
trifugation, and stored at −20 °C until further analysis.
Antigens and peptides
Three soluble recombinant proteins and eight peptides 
conjugated to bovine serum albumin (BSA) specific to 
P. falciparum, P. malariae and A. gambiae salivary pep-
tide gSG6 antigen (Ag) were included. BSA provided by 
peptide manufacturer was used as carrier control. The 
peptides used in this study were designed as already 
described [11]. A N-terminal cysteine residue was added 
to allow a unidirectional coupling to BSA and was done 
by the manufacturer (GenScript HK Inc.,Hong Kong, 
China,). Purity of each BSA-peptide was estimated >85 % 
by HPLC and mass spectrometry. The sequence of the 




Table 1 Context and characteristics of the study population
* Long-lasting impregnated nets: individual inquiry for use of bed nets before consultation
** The mean national level of prevalence of clinical malaria in Ivory Coast is 10.57 % (2013)
Characteristics Abobo Korhogo Man
Geographical situation Township Abidjan Northern Savannah Western forest
N° patients 31 32 31
N° children <5 years old 3 5 10
Age mean–median (range) 14–9.5 (2–54) 19.6–10.5 (1–70) 13.9–10 (1–59)
Mean parasitaemia and 103,706 28,474 52,336
[range parasitaemia] (in trophozoite per mL) (3480–832,000) (2030–92,800) (247–465,800)
Haemoglobin: mean [range]–G/L 10.9 (8.1–12.9) 10.7 (6.3–16.1) 9.2 (6.0–12.5)
Thrombocytes: mean [range]–103/μL 141 (32–309) 188 (37–530) 189 (26–536)
Duration of transmission season All year 6–8 months 8–12 months
Individual use of LLINs* 27 % 10 % 20 %
Prevalence of clinical malaria** 5.2 % 14.7 % 18.3 %
% individuals with parasite clearance >24 h 90 % 13 % 32 %






P. malariae CSP: (NAAG)9–NDAGC and
A. gambiae salivary peptide 1 (gSG6-P1): EKVWVDRDN 
VYCGHLDCTRVATFC.
The procedure for production and purification of the 
NTS–DBL1α1 domain of the PfEMP1 (P. falciparum 
Erythrocyte Membrane Protein-1) adhesin encoded 
by the 3D7/PF13 var gene has been reported elsewhere 
[27]. Soluble recombinant protein corresponding to P. 
falciparum MSP1p19 and MSP4p20 was produced in the 
baculovirus/insect cell expression system and purified by 
metallo-affinity chromatography as described [28].
Coupling of antigen to beads
The covalent coupling of three recombinants antigens 
(PF13, PfMSP4p20 and PfMSP1p19) Ags and all the 
eight peptides to carboxylated magnetic Luminex micro-
spheres by the carbodiimide reaction (Luminex Corp, 
Austin, USA) was done using the xMAP®Antibody Cou-
pling Kit (ref 4050016, Luminex Corp, Austin, USA) 
according to the manufacturer’s instructions as already 
detailed by Perraut et  al. (25). Briefly, 2.5  ×  106 beads 
from regions 26 to 39 were used in a working volume of 
500 µL. All washing steps, buffer changing after 1–2 min 
centrifugation at 8000×g, magnetic pelletting with the 
Luminex® Magnetic plate separator (Luminex Corp, 
Austin, USA), vortexing and sonication in water-bath 
sonicator to disperse the beads was done following man-
ufacturer’s instructions. After carbodiimide hypochloride 
(EDC) activation step, 5 µg of Ag per million beads was 
added in the activation buffer and kept under rotation 
mixing in the dark for 2  h. After pelletting and wash-
ing, the supernatant was removed and replaced by 1 mL 
wash buffer and kept in the dark at 2–8  °C. Final count 
of remaining beads using cell counter showed a mean 
recovery of 98 % of the coupled beads. Efficient coupling 
of Ag was controlled using positive individual and pool of 
human sera. The coupled microspheres were kept in the 
washing/storage buffer at 4 °C in the dark until use.
Bead‑based assay for IgG antibodies
The custom-made Magnetic Bead-based MAGPIX®-
Luminex Assay (MBA), performed in a dimly lit room, 
has been adapted to parallel the working steps used in the 
standard ELISA technique as previously described [24]. 
Plates included two positive controls: a pool of human 
Immune IgG (kind gift from Prof M Hommel) and a 
pool of 25 sera from clinically immune adults living in 
the village of Dielmo (a holo-endemic area of transmis-
sion in Senegal). Pools of European and African non-
immune sera were included as negative control. Briefly, 
2.5 µL aliquots containing 3000 beads per Ag from mix of 
microspheres, kept in an opaque vial, were dispensed to 
individual wells of a white, polystyrene, opaque, round-
bottomed microtitre plate (Ref 103977741, Fisher Scien-
tific, Illkirch, France). Duplicates of 100 μL plasma diluted 
1:100 in PBS Tween 0.01 % BSA 1 % (PBSB) was added 
in wells, mixed and incubated with the beads protected 
from light on a microplate shaker (IKA®MTS, Wilming-
ton, NC, USA) at 350 rpm for 45 min. After removal of 
plasma and two washing steps with 100 μL PBSB, 100 μL 
of phycoerythrin-labelled goat anti-human IgG diluted 
1:500 in PBSB was added (gamma-chain specific, F(ab`)2 
from Sigma, P-8047 St. Louis, MO, USA) and incubated 
in the dark with shaking at 350 rpm for 45 min. After two 
washes with 100  μL/well of PBSB, the beads were then 
resuspended in 120 μL PBSB and analysed on a Multiplex 
MAGPIX system (Millipore, USA) using the xPONENT 
4.1 manufacturer’s software for acquisition. Antibody 
responses were expressed in median fluorescence inten-
sity (MFI) per sample; individual positivity was consid-
ered when the signal was greater than [mean MFI signal 
+3 SD of 6 naïve control sera] as already described [12].
ELISA procedure
IgG responses were quantified by ELISA in duplicate 
plasma samples diluted 1:100 as previously described 
using whole parasite extract Ag from schizonts 07/03 
Dielmo strain adapted to culture [21, 29, 30]. The same 
positive and negative controls used for MBA were 
used in each assay as standards for plate comparability: 
pool of sera from adults living in the village of Dielmo, 
immune IgG (kind gift from Prof M Hommel) and pools 
of European and African non-immune sera. Results were 
expressed as OD ratio  =  OD sample/OD naive serum 
pool [30, 31]. Sera showing an OD ratio >2 were con-
sidered sero-positive, corresponding to the mean OD of 
naïve controls +2 SD.
Statistical analysis
Antibody levels and prevalence of responders in different 
groups were compared using the Mann–Whitney signed 
rank test, the Spearman rank correlation test for non-
normally distributed paired data and the Fisher exact 
test. In case of multiple associated comparisons, Bonfer-
roni correction was applied. Statistical analyses were per-
formed using Statview 5.0 (SAS Institute Inc. 2011. Base 
SAS® 9.3 Procedures Guide. Cary, NC: SAS Institute Inc.) 
and R (R Core Team. R: a language and environment for 
statistical computing. R Foundation for statistical com-
puting. Vienna, Austria. 2014).
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To study the correlation between level of parasitaemia 
and levels of antibody responses, a log transformation 
was used. The log-transformed data were shown distrib-
uted according to normal law using Shapiro–Wilk test. 
So these variables were transformed into normally dis-
tributed variables before being included in the models. 
Generalized linear model was used to compare parasitae-
mia level (considered as dependent variable) to each clin-




Recruitment was done after the rainy season for 30 
patients per village, a limited proportion of children 
under 5 years old were included, except in Man (ten chil-
drens vs five and three in Khorogo and Abobo, respec-
tively). Mean age of the three groups was similar without 
any significant difference in the age distribution between 
the three settings (Table 1).
As shown in Table  1 and Fig.  1, levels of parasitae-
mia measured upon recruitment were highly variable, 
with significantly lower levels in Korhogo, compared to 
the other settings (P  <  10−3). These three settings are 
high risk for malaria, the prevalence of clinical malaria 
in Abobo is approximately 50  % lower than the mean 
national level and 150  % lower compared to the rural 
villages. Of note, urban patients recruited in Abobo suf-
fered highly parasitic clinical episodes: 10 and 30 % of the 
patients harboured <10,000 or >100,000 trophozoites per 
μL, respectively, compared to 26 and 16 % in Man, and 56 
and 0 % in Korhogo for these cut-off parasitaemia levels.
Importantly, treatment was highly efficient: 55, 42 and 
3  % of patients overall cleared their parasitaemia in 24, 
48 and 72 h, respectively. As detailed in Table 1, the most 
efficient clearance of parasites was observed in Korhogo 
followed by Man and then Abobo villages.
Prevalence of antibody responses
Prevalence of antibody responses in the three settings 
against the 12 biomarkers is summarized in Table 2. Prev-
alence levels were highly variable, ranging from 3 % (IgG 
to gSG6 peptide) to 97 % (IgG to MSP4p20). For each set-
ting, the overall mean level of prevalence increased from 
37 % in Man, 42 % in Abobo, to 66 % in Korhogo.
As detailed in Table 2, statistical comparisons of preva-
lence regarding individual biomarkers showed almost no 
significant differences between Man and Abobo except 
for LSA141. In Korhogo, prevalence of antibody responses 
was significantly higher compared to the two other vil-
lages for CSP, LSA141, SALSA, AMA1, MSP4p20, and 
P. malariae CSP. Prevalence of responders to PF13 was 
significantly lower in Abobo (45  %) compared to the 
two other settings (71  %, 91  % in Man and Korhogo, 
respectively).
Levels of IgG antibodies responses in the three settings
Levels of antibody responses are summarized in Table 2, 
they are stated as Mean values and range [minimum–
maximum] in ODratio and MFI. Comparison of levels 
of antibody responses are illustrated in Fig. 1 as box plot 
for all antigens (Fig. 1a, b, c) and whole parasite extract 
(Fig.  1e). As evidenced in Fig.  1, there are strong and 
selectively higher antibody responses against all bio-
markers in individuals from the village of Korhogo, com-
pared to the other settings (P < 10−3). When comparing 
responses to biomarkers in Abobo vs Man, no significant 
differences appeared except for PF13 (P = 0.04). Of note, 
the IgG response against whole parasite extract (from 
Senegalese strain 07/03) did not significantly discrimi-
nate any significant high level of antibody response in 
Korhogo as did the set of biomarkers.
Inter‑relation of antibody responses and correlation 
of antibody responses with age
Results of analysis for inter-relation between antibody 
responses against the different targets and the age of 
individuals are detailed in Table 3. The results calculated 
after Bonferroni correction for multiple comparisons 
was also included. There was no significant correlation 
between age and antibody responses against all targets 
except for GLURP peptide (rho = 0.5, P < 10−3). As sum-
marized in Table  3, a strong interrelation between anti-
body responses to almost all target antigens was found, 
with an exception for somatic antigen and MSP1p19. 
Inter-relation between antibody responses was not sig-
nificant for whole schizont extract antigen and MSP1p19; 
it was intermediate for LSA3 and GLURP peptides.
Relationship of antibody responses with circulating 
parasitaemia, haematological measures and clinical criteria
There was no correlation between parasitaemia observed 
at recruitment (or log-transformed parasite density) with 
antibody responses against all antigens except a signifi-
cant negative correlation with IgG responses to LSA3 
(P < 10−3) rho = −0.35 and PF13 (P < 10−4) rho = −0.41.
When stratifying parasite densities under and over 
50,000 trophozoites per μL, only antibody responses 
to PF13 remained significantly lower (P = 0.01) in indi-
viduals with high levels of parasites (approximately one-
third of the overall cohort). A significant relationship 
was found between parasitaemia and thrombocytaemia 
(P < 0.001), thrombocytaemia decreased when parasitae-
mia increased.
The relationship between immune responses and 
the efficiency of treatment was analysed by stratifying 
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clearance of parasitaemia between early (<24 h) and later 
(48–72 h) delay of blood smear negativation. As shown in 
Fig. 2, there was a general trend for higher antibody levels 
in individuals with rapid clearance. In this group, higher 
levels were found significant for 50 % of the biomarkers, 
i.e., LSA3, SALSA, AMA1, PF13, MSP4p20, and PmCSP.
When investigating correlates with the records of 
clinical signs, a significant relationship was found only 
between parasitaemia and nausea (P < 0.01), parasitaemia 
was higher in patients with nausea. In the multivariate 
analysis, studying the relationship of parasitaemia with 
PF13, LSA3, thrombocytaemia, nausea, village, the last 
model was based only on PF13 and thrombocytaemia. 
Parasitaemia decreased with PF13 level and increased 
when thrombocytaemia decreased.
Discussion
The present study was undertaken to draw a first pro-
file of antibody responses to a large array of antigens in 
three sentinel settings for malaria national surveillance 
and treatment in Ivory Coast, a country with a high level 
of endemicity [4]. There are few large-scale studies ana-
lysing precisely the prevalence of P. falciparum malaria 
and its recent history in Ivory Coast. However, observed 
P. falciparum prevalence in previous surveys from cen-
tral and south-central Ivory Coast [1, 32, 33] underlined 
that malaria is highly endemic and characterized by con-
siderable heterogeneity. In addition, the complex local 
social-ecological contexts, including population influx, 
might play a role resulting in an increase of presumed 






























































































Fig. 1 Mean levels of IgG responses to biomarkers and of parasitaemia in the three different sentinel sites. Antibody responses measured with 
multiplex magnetic bead based fluorescence assay are shown as box plot for median fluorescence levels (MFI) for the three settings, i.e., Abobo 
(light grey), Korhogo (black) and Man (dark grey). Antibody responses to pre‑erythrocytic/erythrocytic antigens, P. malariae CSP and A. gambiae 
salivary peptide are shown in Part (a) and (b) (lower levels of MFI). In Part c, antibody responses to erythrocytic antigens are shown. Mean levels of 
parasitaemia and levels of antibody responses against whole schizont extract antigen are plotted in Part d and e, respectively. Asterisks or asterisk 
with bracket above bar charts indicate significant (P < 0.05) differences in levels of antibodies
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and 2013, respectively [4]. Transmission can also change 
depending upon climate and rainfall [34], as well as 
potential changes of vector behaviour, such as adaptation 
of A. gambiae to polluted water [35] or the strong natu-
ral heterogeneity in entomologic parameters of malaria 
transmission [36].
In this context, affordable tools for evaluation and 
monitoring of malaria control interventions, such as 
immune biomarkers, can play a valuable role [9–11, 14]. 
Indeed, individual risk of infective bites depends substan-
tially of the use of bed nets, and here the proportion of 
use was declared <30 % and slightly different between the 
settings Abobo > Man > Korhogo (Table 1). In addition, 
deep change in behaviour of A. gambiae sub-population 
can add a possible source of increasing transmission [37].
Recruitment of patients with non-severe clinical 
malaria was a first pilot approach, regarding which clini-
cal infection by P. falciparum strongly stimulates immune 
responses against all components of the parasite. Thus, 
all patients had a comparable, individual, clinical sus-
ceptibility to infection that necessitated consultation 
and hospitalization, independently of the setting and the 
individual natural history of infection. There was a clear 
and highly significant, unexpected, difference of antibody 
responses between one of the setting (Korhogo) and the 
other two.
Most sero-epidemiology studies rely on cross-sec-
tional or longitudinal follow-up of individuals before 
or after clinical episodes, including prospective analy-
sis to establish relationship between antibody responses 
against one antigen [17–19, 21–23, 38] or several anti-
gens and protection against clinical malaria [20, 39]. 
Excepting individuals with active asymptomatic para-
site carriage, almost all studies involve a relatively stable 
state in host-parasite interaction, an approach in which 
serological analyses are potentially relevant indicators 
of malaria transmission [10, 40]. For example, a single 
antigen AMA1 has been used for mapping effective-
ness of control intervention [41]; in another case, several 
antigens were used as markers of exposure and malaria 
risk [39]. A similar methodology was undertaken in this 
study, underlining a clear significant higher immuno-
logical background in Korhogo. In this site, transmis-
sion reflected by prevalence of clinical malaria, was high 
but slightly lower than in Man. Here, as the recruitment 
involved symptomatic cases, antibodies measured against 
targeted antigens may play no causal role in protection 
but rather reflect the individual boosting capacity of 
immune responses. A higher level of antibody responses 
against the set of antigens was found in individuals with 
significantly stronger immune background but still sus-
ceptible to parasite invasion with clinical attack. This 
could explain the absence of relationship between parasi-
taemia and antibody responses observed, despite signifi-
cant inter-relation between antibody responses.
Interestingly, the whole parasite extract from 07/03 
in vitro-adapted strain from Dielmo has been already used 
as a relevant marker for follow-up of immunity levels [29, 
42, 43], but did not correlate with clinical protection in 
prospective studies [21]. In Ivory Coast, levels and preva-
lence of antibody responses to the whole parasite extract 
did not show any difference between the three settings, 
contrary to defined antigens in Korhogo. Such discrepancy 
could be related to some substantial difference between this 
Table 2 Levels and prevalence of IgG antibody responses in the different sentinel sites
P Significant differences of prevalence by Fisher exact test
a Abobo vs Korhogo, b Korhogo vs Man, c Man vs Abobo, d NS non-significant, e ELISA measure of antibody responses against schizont extract expressed as mean OD 
ratio, f Mean [minimum–maximum] antibody responses expressed in OD ratio (schizont extract) and MFI
Antibody responses to Abobo Korhogo Man
IgG levelsf % Pa IgG levels % Pb IgG levels % Pc
Scz_Age 4.1 (1–7.3) 84 NSd 3.9 (1–10.4) 81 NS 3.6 (1–11) 68 NS
CSP 110 (16–920) 26 <10−3 602 (26–2834) 75 <10−3 133 (21–2139) 13 NS
LSA141 376 (22–1475) 61 <0.05 1112 (31–8171) 84 <10
−3 188 (27–1774) 32 <0.04
LSA3 70 (16–676) 10 NS 143 (40–1035) 31 NS 79 (19–637) 10 NS
SALSA 112 (18–886) 19 <10−3 785 (26–7656) 59 <0.004 74 (22–376) 23 NS
AMA1 145 (21–814) 39 <10−3 713 (47–3337) 84 <10−3 142 (37–747) 35 NS
GLURP 403 (20–2006) 45 NS 1485 (38–7701) 50 NS 344 (29–1440) 35 NS
MSP1p19 1031 (34–2834) 81 NS 2203 (77–9058) 88 NS 946 (42–3305) 68 NS
MSP4p20 817 (22–4231) 77 <0.03 3125 (90–10,674) 97 0.013 831 (49–2455) 74 NS
PF13 351 (21–3820) 45 <10−3 1887 (67–10,036) 91 NS 402 (33–1601) 71 NS
CSP P. malariae 60 (24–370) 10 <0.016 232 (33–3202) 38 <0.005 47 (25–267) 6 NS
gSG6 An. gambiae 66 (18–219) 6 NS 126 (25–452) 16  NS 83 (25–744) 3 NS
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particular Senegalese strain and the circulating strains in 
Ivory Coast. This observation has to be further confirmed 
by testing a reference strain and/or a locally adapted strain.
One main question raised by the measure of multiplex 
reactogenicity profile on day of consultation is the search 
for potential immune marker(s) able to predict a differen-
tial susceptibility to the observed level of infection. Only 
two antigens induced antibody responses significantly 
different between the sites of Abobo and Man: the inci-
dence of responders to LSA141 and the levels of antibody 
responses to PF13. PfEMP1–PF13 antigen was shown as 
a relevant biomarker of cumulative acquisition of immu-
nity in endemic setting [27, 44] and appeared significantly 
related to parasite levels. Such capacity has to be further 
confirmed with larger cohorts from more settings.
Susceptibility to infection can be reflected by the level 
of parasitaemia and by the degree of individual severity of 
clinical signs. The level of parasitaemia was significantly 
lower in Korhogo compared to the two other sites and 
there was a clear decreasing gradient of high level para-
sitaemia from Abobo (30 %) to Man (16 %) and Korhogo 
(0 %). The multivariate analysis investigating correlation 
between level of parasitaemia, according to each clinical 
signs and setting, underlined only nausea as a significant 
clinical sign. This is in line with observation that sever-
ity of clinical outcome in a mild malaria episode is not 
related to the level of parasitaemia or acquired immunity, 
once susceptible [45]. However, despite substantial differ-
ence in the magnitude of parasite invasion according to 
the setting, treatment was 100 % efficient by 72 h. Within 
the period covered by this study, there was no indication 
of delayed response to artemisinin combination therapy 
(ACT). Parasites were cleared rapidly, leaving very few 
patients with a low parasitaemia on day 3: only 1.5 % of 
the patients were still positive on day 3 which is under 
the threshold of 3 % indicating delayed response [46].
Importantly, this study shows clearly the potential 
impact of host immunity on malaria treatment out-
come. A fast clearance of circulating parasite (24 h) was 
associated with higher level of immunity. This general 
trend, shown in Fig.  2, was significant for 50  % of the 
biomarkers. These results are in agreement with several 
studies involving sulfadoxine–pyrimethamine or amo-
diaquine treatment, showing a significant association 
of higher levels of antibodies to GLURP [47], AMA1 
[48] and MSP1 [49] antigens with a lower risk of treat-
ment failure. Another study showed the contribution of 
antibodies to the Ring Erythrocyte Surface antigen to 
the therapeutic response in Thai patients treated with 
artesunate [50]. Indeed, the positive contribution of 
host immunity for rapid parasite clearance underlined 
in this study is outlined by multi-site recruitment test-
ing, contrary to previous investigations [47–50]. The use 
of antibody responses to biomarkers underlined clearly 
the site of Korhogo as different from the other two; 
parasite transmission seems to remain high, marked by 
higher boosting capacity of antibody responses. Such 
observation could possibly be related to lower applica-
tion of individual prevention measures. This was con-
firmed by a two–three-times lower utilization of bed 
nets, as recorded by individual questionnaire, and the 
differential impact on antibody responses to gSG6 sali-
vary peptide. However, such individual behaviour has to 
be further confirmed. Serological tools, such as Anoph-
eles salivary peptide gSG6-P1 antigen, have been shown 
to be a new relevant marker of risk for malaria trans-
mission [5–7, 51–53]. A significant higher level of IgG 
against the salivary peptide in Korhogo compared to 
other villages was found. However, seroprevalence did 
not significantly differ and MFI levels were low com-
pared to other biomarkers. This lower sensitivity may be 
related to the intrinsic multiplex technique compared to 
ELISA, based on a high concentration of peptide coat-
ing (20  µg/Ml) and lower serum dilution for detection 















































Fig. 2 Distribution of IgG responses against biomarkers as function 
of delay for parasite clearance after treatment. Dichotomization of 
antibody responses expressed as mean median fluorescence levels 
(MFI) are plotted as box plot for the overall cohort of patients as func‑
tion of either early clearance (24 h, dark grey) or later clearance (48 
and 72 h, light grey). Asterisks indicate a significant (P < 0.05) different 
level of antibody level
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using this biomarker may rather require ELISA than 
MBA for enhanced sensitivity.
Accurate analysis of immune responses from malaria 
symptomatic individuals can underline heterogeneity in 
individual degree of exposure and bring important infor-
mation on the effective application of control measures at 
a community level.
Conclusion
This pilot study suggests that measures of antigen reac-
tivity profiles using the MBA can conveniently contribute 
to follow-up and monitoring of integrated malaria con-
trol measures. A panel of antigens, covering targets from 
different parasite stages is preferentially required, includ-
ing antigens from other Plasmodium species. However, 
further investigations are required, including antigen 
targets from other species, enlarged to multiple sites and 
comprising enrolment of young individuals. Immunity 
profiling using biomarkers has the potential for immuno-
logical mapping of intervention and help with prevention 
measures towards malaria elimination.
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